Novo Nordisk's Wegovy wins FDA approval for heart disease

Novo Nordisk garnered a major boost for its runaway success in obesity drugs with FDA approval of a label expansion for Wegovy for reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).

This could drive a major increase in insurance coverage for Wegovy patients, plus much wider reach among patients already suffering from the above indications

The updated label will reflect a 15% risk reduction in cardiovascular death and a 19% risk reduction of death from any cause, both vs. placebo